Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

摘要: ABSTRACTIntroduction: Systemic lupus erythematosus (SLE) is an autoimmune disease affecting different organs. The improved knowledge of the disease’s pathogenesis has contributed to emergence immune targets and new biologic drugs directed at them. Although rheumatologists continue use off-label biologics in SLE resistant other immunosuppressants, only belimumab been approved as a biological therapy since 2011.Areas covered: In this review, overview provided on: 1) classification clinical trials those under research; 2) results with interpretation pitfalls syntheses potential approaches overcome these and, 3) commonly used activity metrics composite indices for assessing response drugs.Expert opinion: Some that have failed previous drug shown be efficacious treatment observational studies. Moreover, post-hoc analyses...